BLRX
BioLineRx Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-59/100
Last price
2.29
▼ 0.01 (0.35%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
2.30
Day high
2.40
Day low
2.26
Volume
22.82K
Market cap
$11.41M
P/E (TTM)
—
52W range
2.15 – 4.54
Trailing performance
Returnvs SPY
1W
-2.97%
-4.9%
1M
-14.23%
-15.4%
3M
-23.92%
-28.4%
6M
+0.88%
-17.3%
YTD
-17.33%
-31.6%
1Y
-42.75%
-59.2%
3Y
-96.85%
-179.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BLRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
149.83K
Total on file
Fundamentals
Market cap$11.41M
Enterprise value$7.73M
Revenue (TTM)$1.39M
Gross profit$1.11M
EBITDA$-12.12M
Net income$-6.99M
EPS (TTM)$0.00
Free cash flow$-8.85M
Total cash$13.08M
Total debt$7.94M
Book value / share$3.00
Shares outstanding4.98M
Float4.14M
Short % of float3.01%
Dividend yield0.00%
Beta (5Y)0.70
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.91
PEG ratio—
Price / sales—
Price / book0.76
EV / revenue5.55
EV / EBITDA-0.64
Gross margin80.03%
Operating margin-1215.31%
Profit margin0.00%
Return on equity-55.27%
Return on assets-19.82%
Debt / equity47.78
Current ratio1.20
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.18M | $28.94M | $4.80M | $0 | -95.9% |
| Operating revenue | $1.18M | $28.94M | $4.80M | $0 | -95.9% |
| Cost of revenue | $230.00K | $9.26M | $3.69M | $0 | -97.5% |
| Gross profit | $950.00K | $19.68M | $1.11M | $0 | -95.2% |
| Research & development | $8.09M | $9.15M | $12.52M | $17.63M | -11.5% |
| Selling, general & admin | $3.92M | $28.54M | $31.23M | $11.49M | -86.3% |
| Total operating expense | $11.24M | $38.83M | $44.10M | $29.16M | -71.1% |
| Operating income | -$10.29M | -$19.15M | -$42.99M | -$29.16M | +46.3% |
| Net interest income | -$156.00K | -$7.30M | -$162.00K | -$1.12M | +97.9% |
| Pre-tax income | -$2.03M | -$9.22M | -$60.61M | -$24.95M | +78.0% |
| Net income | -$1.18M | -$9.22M | -$60.61M | -$24.95M | +87.3% |
| Net income to common | -$1.18M | -$9.22M | -$60.61M | -$24.95M | +87.3% |
| Basic EPS | 0.00 | -6.00 | -36.00 | -18.00 | +100.0% |
| Diluted EPS | 0.00 | -6.00 | -36.00 | -18.00 | +100.0% |
| EBIT | -$775.00K | -$147.00K | -$58.47M | -$23.16M | -427.2% |
| EBITDA | -$252.00K | $3.92M | -$57.09M | -$22.51M | -106.4% |
| Basic shares | 4.11M | 2.00M | 1.61M | 1.29M | +105.8% |
| Diluted shares | 4.11M | 2.00M | 1.61M | 1.29M | +105.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.25M | $10.44M | $4.25M | $10.59M | -68.9% |
| Cash & short-term investments | $20.88M | $19.56M | $42.99M | $51.08M | +6.7% |
| Accounts receivable | $46.00K | $2.48M | $358.00K | $0 | -98.1% |
| Inventory | $2.15M | $3.15M | $1.95M | $0 | -31.7% |
| Total current assets | $23.68M | $27.10M | $47.18M | $52.00M | -12.6% |
| Property, plant & equipment | $856.00K | $1.35M | $1.89M | $2.50M | -36.7% |
| Goodwill & intangibles | $16.37M | $10.45M | $14.85M | $21.89M | +56.6% |
| Total assets | $40.91M | $38.91M | $63.92M | $76.38M | +5.1% |
| Total current liabilities | $12.12M | $15.41M | $42.78M | $10.68M | -21.3% |
| Current debt | $4.48M | $4.48M | $3.15M | $1.54M | 0.0% |
| Long-term debt | $4.46M | $8.96M | $6.63M | $8.63M | -50.2% |
| Total debt | $10.15M | $15.04M | $11.59M | $12.32M | -32.5% |
| Total liabilities | $17.56M | $25.45M | $50.70M | $25.54M | -31.0% |
| Retained earnings | -$401.00M | -$399.83M | -$390.61M | -$329.99M | -0.3% |
| Shareholder equity | $18.20M | $13.46M | $13.22M | $50.84M | +35.2% |
| Working capital | $11.56M | $11.70M | $4.40M | $41.32M | -1.2% |
| Net tangible assets | $1.83M | $3.01M | -$1.63M | $28.96M | -39.3% |
| Shares issued | 2.61B | 1.34B | 1.09B | 922.96M | +95.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$2.03M | -$9.22M | -$60.61M | -$24.95M | +78.0% |
| Depreciation & amortisation | $523.00K | $4.07M | $1.38M | $654.00K | -87.1% |
| Stock-based compensation | $396.00K | $1.14M | $2.32M | $2.25M | -65.1% |
| Change in working capital | $1.26M | -$21.82M | $15.20M | $1.24M | +105.8% |
| Operating cash flow | -$8.07M | -$43.87M | -$22.61M | -$26.24M | +81.6% |
| Capital expenditure | -$27.00K | -$54.00K | -$297.00K | -$316.00K | +50.0% |
| Investing cash flow | -$8.54M | $29.37M | $1.44M | $4.01M | -129.1% |
| Financing cash flow | $8.88M | $20.66M | $15.06M | $20.44M | -57.0% |
| Free cash flow | -$8.10M | -$43.93M | -$22.91M | -$26.56M | +81.6% |
| End cash position | $3.25M | $10.44M | $4.25M | $10.59M | -68.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $294.00K | $477.00K | $194.00K | $427.00K | $304.00K | — | -38.4% |
| Operating revenue | $294.00K | $477.00K | $194.00K | $427.00K | $304.00K | — | -38.4% |
| Cost of revenue | $59.00K | $95.00K | $40.00K | $84.00K | $72.00K | — | -37.9% |
| Gross profit | $235.00K | $382.00K | $154.00K | $343.00K | $232.00K | — | -38.5% |
| Research & development | $2.94M | $2.53M | $2.42M | $1.72M | $2.33M | — | +16.4% |
| Selling, general & admin | $865.00K | $858.00K | $1.89M | $831.00K | $209.00K | — | +0.8% |
| Total operating expense | $3.81M | $3.39M | $3.54M | $2.55M | $2.54M | — | +12.5% |
| Operating income | -$3.57M | -$3.00M | -$3.39M | -$2.21M | -$2.30M | — | -18.9% |
| Net interest income | -$76.00K | -$42.00K | -$317.00K | $73.00K | $214.00K | — | -81.0% |
| Pre-tax income | -$4.34M | -$2.59M | -$2.24M | -$977.00K | -$3.94M | — | -67.7% |
| Net income | -$3.03M | -$1.60M | -$1.39M | -$977.00K | -$3.94M | — | -89.0% |
| Net income to common | -$3.03M | -$1.60M | -$1.39M | -$977.00K | -$3.94M | — | -89.0% |
| Basic EPS | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Diluted EPS | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EBIT | -$4.13M | -$2.34M | -$1.99M | -$673.00K | -$3.66M | — | -76.7% |
| EBITDA | -$4.05M | -$2.25M | -$1.92M | -$554.00K | -$3.49M | — | -80.1% |
| Basic shares | 4.44M | 4.43M | — | 4.35M | 3.95M | 3.70M | +0.2% |
| Diluted shares | 4.44M | 4.43M | — | 4.35M | 3.95M | 3.70M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.63M | $2.50M | $3.25M | $7.91M | $7.19M | — | +84.8% |
| Cash & short-term investments | $13.08M | $17.35M | $20.88M | $25.21M | $28.16M | — | -24.6% |
| Accounts receivable | — | — | $46.00K | $0 | $78.00K | $1.47M | — |
| Inventory | $2.17M | $2.16M | $2.15M | $2.18M | $2.85M | — | +0.5% |
| Total current assets | $16.35M | $21.58M | $23.68M | $28.52M | $31.86M | — | -24.2% |
| Property, plant & equipment | $803.00K | $867.00K | $856.00K | $892.00K | $997.00K | — | -7.4% |
| Goodwill & intangibles | $16.33M | $16.35M | $16.37M | $10.39M | $10.41M | — | -0.1% |
| Total assets | $33.48M | $38.80M | $40.91M | $39.80M | $43.27M | — | -13.7% |
| Total current liabilities | $13.68M | $13.62M | $12.12M | $13.67M | $15.48M | — | +0.4% |
| Current debt | $4.48M | $4.48M | $4.48M | $4.48M | $4.48M | — | 0.0% |
| Long-term debt | $2.22M | $3.36M | $4.46M | $5.60M | $6.72M | — | -33.9% |
| Total debt | $7.94M | $9.07M | $10.15M | $11.38M | $12.60M | — | -12.4% |
| Total liabilities | $16.86M | $17.96M | $17.56M | $20.27M | $23.20M | — | -6.1% |
| Retained earnings | -$405.63M | -$402.60M | -$401.00M | -$399.62M | -$398.64M | — | -0.8% |
| Shareholder equity | $13.77M | $16.67M | $18.20M | $19.53M | $20.07M | — | -17.4% |
| Working capital | $2.67M | $7.96M | $11.56M | $14.86M | $16.38M | — | -66.4% |
| Net tangible assets | -$2.56M | $325.00K | $1.83M | $9.14M | $9.66M | — | -887.1% |
| Shares issued | 2.62B | 2.61B | 2.61B | 2.61B | 2.23B | — | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$4.34M | -$2.59M | -$2.24M | -$977.00K | -$3.94M | -67.7% |
| Depreciation & amortisation | $78.00K | $88.00K | $63.00K | $119.00K | $176.00K | -11.4% |
| Stock-based compensation | $79.00K | $78.00K | $48.00K | $101.00K | $53.00K | +1.3% |
| Change in working capital | $285.00K | $513.00K | $79.00K | -$177.00K | $1.87M | -44.4% |
| Operating cash flow | -$3.22M | -$2.28M | -$3.20M | -$2.11M | -$177.00K | -41.1% |
| Capital expenditure | — | -$6.00K | — | — | — | — |
| Investing cash flow | $6.35M | $2.70M | -$337.00K | $3.67M | -$3.70M | +134.9% |
| Financing cash flow | -$1.14M | -$1.18M | -$1.25M | -$916.00K | $1.60M | +3.4% |
| Free cash flow | -$3.21M | -$2.29M | -$3.23M | -$2.11M | -$177.00K | -40.5% |
| End cash position | $4.63M | $2.50M | $3.25M | $7.91M | $7.19M | +84.8% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
+118.1% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
1
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | — | 0.00 | — |
| Mar 2026 | -1.04 | 0.00 | +100.0% |
| Dec 2025 | -0.77 | 0.00 | +100.0% |
| Sep 2025 | -0.54 | 0.00 | +100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.77 | 1 | $357.50K | -16.3% |
| Next quarter | -0.80 | 1 | $492.50K | +153.9% |
| Current year | -3.14 | 1 | $1.62M | +37.3% |
| Next year | -2.52 | 1 | $2.22M | +37.1% |
Analyst targets & ownership
Mean target$22.00
High target$26.00
Low target$18.00
Implied upside859.86%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders3.43%
Held by institutions1.34%
Institutions holding14
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.41
-5.09% from price
SMA 20
2.46
-6.80% from price
SMA 50
2.63
-13.04% from price
SMA 100
2.88
-20.37% from price
SMA 200
2.81
-18.61% from price
EMA 12
2.40
-4.66% from price
EMA 26
2.50
-8.29% from price
EMA 50
2.62
-12.35% from price
RSI (14)
36.2
Neutral
MACD (12,26,9)
-0.09
Hist -0.01
ATR (14)
0.13
5.55% of price
Realised vol 30D
49.3%
Annualised
Bollinger upper
2.64
20, 2σ
Bollinger lower
2.28
20, 2σ
50 / 200 cross
Death
2.63 vs 2.81
Trend bias
Below 200
-18.61%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.58
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
49.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-50.9%
Peak to trough
Max drawdown 5Y
-98.2%
Peak to trough
ATR 14
0.13
5.55% of price
Beta (reported)
0.70
5Y monthly, from filing
Short interest
Shares short
145.80K
Prior 134.58K
Change vs prior
+8.3%
Shorts adding
% of float
3.01%
Normal
% of shares out
3.01%
Against total outstanding
Days to cover
5.2
Crowded exit
Float
4.14M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 17, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 30, 25 | Jones Trading | UPGRADE | Hold | Buy |
| May 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 2, 25 | Jones Trading | DOWNGRADE | Buy | Hold |
| Mar 31, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 25, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 6, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 3, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 29, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 17, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 26, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 29, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJul 15, 2019
Last split1:40
Split dateJan 30, 2025
SEC filings
Offering Registrations
F-1 · 2026-09-25
Corporate Changes & Voting Matters
6-K · 2026-09-24
Corporate Changes & Voting Matters
6-K · 2026-09-10
Additional Forms
D · 2026-09-09
Corporate Changes & Voting Matters
6-K · 2026-08-28
Corporate Changes & Voting Matters
6-K · 2026-08-18
Corporate Changes & Voting Matters
6-K · 2026-07-08
Corporate Changes & Voting Matters
6-K · 2026-05-27
Headlines
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
PR Newswire · 27d ago
BLRX: New GLIX1 Data Touts Synergies
Zacks Small Cap Research · 36d ago
BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ...
GuruFocus.com · 36d ago
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire · 37d ago
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
PR Newswire · 40d ago
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
PR Newswire · 43d ago
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
PR Newswire · 79d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.